Bayer increases sales and earnings – leader in agriculture after acquisition

  • Group sales at €39.6 billion (Fx & portfolio adj. +4.5%)
  • EBITDA before special items increases to €9.5 billion (+2.8%), held back by currency effects of approx. €0.5 billion
  • Pharmaceuticals with higher sales (Fx & portfolio adj.) and slightly lower earnings
  • Consumer Health: sales level with prior year (Fx & portfolio adj.), earnings decline
  • Crop Science reports sales gains, substantially higher earnings due to the acquisition, integration off to a strong start
  • Positive safety profile of glyphosate unchanged – Bayer vigorously defending itself against lawsuits
  • Net income at €1.7 billion, impacted by one-time effects
  • Core earnings per share at €5.94, above expectations
  • Proposed dividend of €2.80 per share, leading to record pay-out
  • Net financial debt at €35.7 billion – significantly better than expected
  • Bayer confirms 2019 Group outlook and 2022 targets


+ 4.5 %

EBITDA Before Special Items

+ 2.8 %

Net Income

1.7 billion

Core Earnings per Share


Proposed dividend of

€2.80 per share, leading to record pay-out

Investment in Research and Development

5.2 billion

1(Fx & portfolio adj.)

Latest Key Data

The interactive chart generator of Bayer AG gives an overview of the key financial and ecological data for the past five years. You can collate the given key data and years yourself in the form of tables, bar charts or line charts. Diagrams can be saved as graphics, tables as Excel documents.

Compare to Last Year